This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Biao Zhu
Zhejiang University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:
Acquired immune deficiency syndrome-related lymphoma (ARL) is closely related to Epstein-Barr virus (EBV) infection. However, there are few studies on the occurrence and development of EBV microRNAs (miRNAs) in ARL patients.
Methods:
The plasma of 5 EBV-infected ARL patients and 8 EBV-infected HIV patients were screened for EBV miRNAs differentially expressed between the two groups through a customized EBV microRNA quantification chip. The plasma of 35 EBV-infected ARL patients and 20 EBV-infected HIV patients was verified by qRT-PCR expanded samples. And we gave a further analysis of the correlation between differentially expressed EBV miRNAs and clinical indicators in ARL patients.
Results:
1. There were differential expressions of EBV miRNAs in the plasma of EBV-infected ARL patients and EBV-infected HIV patients. It was found that ebv-miR-BART2-5p, ebv-miR-BART8-3p, ebv-miR-BART15, ebv-miR-BART19-5p expression was significantly up-regulated and ebv-miR-BART9-5p expression was significantly down-regulated; 2. EBV miRNAs with significantly different expressions in the screening results were expanded and verified by qRT-PCR, and the differential expression was found to be consistent with the screening results; 3. The relative expression levels of ebv-miR-BART8-3p,ebv-miR-BART19-5p and ebv-miR-BART9-5p in plasma were positive correlated with the international prognostic index (IPI) score of Lymphoma, eastern cooperative oncology group (ECOG) scores are the incidence of lymphoma B symptoms (P = 0.03, 0.01, and 0.04, respectively);4. EBV miRNAs could be used as biomarkers for ARL prognosis evaluation.
Conclusions:
The expression of ebv-miR-BART2-5p, ebv-miR-BART8-3p, ebv-miR-BART15, ebv-miR-BART19-5p, ebv-miR-BART9-5p and ebv-miR-BART6-3p in ARL patients were highly different; and ebv-miR-BART8-3p, ebv-miR-BART19-5p, ebv-miR-BART9-5p could be used as the biomarkers of the prognosis of ARL evaluation.
Keywords
EBV, microRNA, lymphoma, HIV, Prognosis
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research Article
Biao Zhu
Zhejiang University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:
Acquired immune deficiency syndrome-related lymphoma (ARL) is closely related to Epstein-Barr virus (EBV) infection. However, there are few studies on the occurrence and development of EBV microRNAs (miRNAs) in ARL patients.
Methods:
The plasma of 5 EBV-infected ARL patients and 8 EBV-infected HIV patients were screened for EBV miRNAs differentially expressed between the two groups through a customized EBV microRNA quantification chip. The plasma of 35 EBV-infected ARL patients and 20 EBV-infected HIV patients was verified by qRT-PCR expanded samples. And we gave a further analysis of the correlation between differentially expressed EBV miRNAs and clinical indicators in ARL patients.
Results:
1. There were differential expressions of EBV miRNAs in the plasma of EBV-infected ARL patients and EBV-infected HIV patients. It was found that ebv-miR-BART2-5p, ebv-miR-BART8-3p, ebv-miR-BART15, ebv-miR-BART19-5p expression was significantly up-regulated and ebv-miR-BART9-5p expression was significantly down-regulated; 2. EBV miRNAs with significantly different expressions in the screening results were expanded and verified by qRT-PCR, and the differential expression was found to be consistent with the screening results; 3. The relative expression levels of ebv-miR-BART8-3p,ebv-miR-BART19-5p and ebv-miR-BART9-5p in plasma were positive correlated with the international prognostic index (IPI) score of Lymphoma, eastern cooperative oncology group (ECOG) scores are the incidence of lymphoma B symptoms (P = 0.03, 0.01, and 0.04, respectively);4. EBV miRNAs could be used as biomarkers for ARL prognosis evaluation.
Conclusions:
The expression of ebv-miR-BART2-5p, ebv-miR-BART8-3p, ebv-miR-BART15, ebv-miR-BART19-5p, ebv-miR-BART9-5p and ebv-miR-BART6-3p in ARL patients were highly different; and ebv-miR-BART8-3p, ebv-miR-BART19-5p, ebv-miR-BART9-5p could be used as the biomarkers of the prognosis of ARL evaluation.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...